Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 1.00 |
| ▸ | MERTK | Q12866 | 1/20 | 1.00 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.67 |
| ▸ | JAK2 | O60674 | 13/20 | 0.66 |
| ▸ | JAK1 | P23458 | 13/20 | 0.66 |
| ▸ | JAK3 | P52333 | 3/20 | 0.63 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.63 |
| ▸ | PAK4 | O96013 | 2/20 | 0.63 |
| ▸ | ABL1 | P00519 | 2/20 | 0.63 |
| ▸ | RET | P07949 | 2/20 | 0.63 |
| ▸ | LTK | P29376 | 2/20 | 0.63 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.63 |
| ▸ | CLK2 | P49760 | 2/20 | 0.63 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.63 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.63 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.63 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.63 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.63 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.63 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16517664 | 1.00 | AXL (1.00) | AXLMERTKTYRO3JAK2JAK1 | |
| SCHEMBL16517815 | 1.00 | AXL (1.00) | AXLMERTKTYRO3JAK2JAK1 | |
| SCHEMBL30819101 | 1.00 | AXL (1.00) | AXLMERTKTYRO3JAK2JAK1 | |
| SCHEMBL29380316 | 1.00 | AXL (1.00) | AXLMERTKTYRO3JAK2JAK1 | |
| SCHEMBL13058317 | 0.92 | AXL (0.85) | AXLMERTKTYRO3JAK2JAK1 | |
| SCHEMBL860616 | 0.92 | AXL (0.85) | AXLMERTKTYRO3JAK2JAK1 | |
| SCHEMBL13058327 | 0.92 | AXL (0.85) | AXLMERTKTYRO3JAK2JAK1 | |
| SCHEMBL860426 | 0.92 | AXL (0.85) | AXLMERTKTYRO3JAK2JAK1 | |
| SCHEMBL859509 | 0.90 | AXL (0.82) | AXLMERTKTYRO3JAK2JAK1 | |
| SCHEMBL17732355 | 0.90 | AXL (0.81) | AXLMERTKTYRO3JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4501409-A2 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | Incyte Holdings Corporation (US) | 2025-02-05 | — | — | EP | claimed |
| EP-3773593-B1 | TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORS | INCYTE CORP (US) | 2024-05-15 | — | — | EP | claimed |
| US-20240091234-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION | 2024-03-21 | — | — | US | claimed |
| US-20240058343-A1 | TREATMENT OF URTICARIA USING JAK INHIBITORS | INCYTE CORPORATION | 2024-02-22 | — | — | US | claimed |
| EP-4274578-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | Incyte Corporation (US) | 2023-11-15 | — | — | EP | claimed |
| US-20220378791-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | INCYTE CORPORATION | 2022-12-01 | — | — | US | claimed |
| US-20220226327-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | INCYTE CORPORATION | 2022-07-21 | — | — | US | claimed |
| WO-2022150676-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | INCYTE CORPORATION (US) | 2022-07-14 | — | — | WO | claimed |
| US-11324749-B2 | Combination therapy for treatment of hematological diseases | INCYTE CORPORATION (US) | 2022-05-10 | — | — | US | claimed |
| EP-3873433-A1 | COMBINATION THERAPY FOR TREATMENT OF HEMATOLOGICAL DISEASES | Incyte Corporation (US) | 2021-09-08 | — | — | EP | claimed |
| US-20190111058-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | INCYTE CORPORATION | 2019-04-18 | — | — | US | claimed |
| US-9498467-B2 | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 | INCYTE CORPORATION (US) | 2016-11-22 | — | — | US | claimed |
| US-9334274-B2 | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-05-10 | — | — | US | claimed |
| US-20160000795-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION (US) | 2016-01-07 | — | — | US | claimed |
| US-20150342952-A1 | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 | INCYTE CORPORATION (US) | 2015-12-03 | — | — | US | claimed |
| US-20150246046-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | INCYTE CORPORATION | 2015-09-03 | — | — | US | claimed |
| US-20150065447-A1 | SURVIVAL BENEFIT IN PATIENTS WITH SOLID TUMORS WITH ELEVATED C-REACTIVE PROTEIN LEVELS | INCYTE CORPORATION (US) | 2015-03-05 | — | — | US | claimed |
| US-20140221379-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2014-08-07 | — | — | US | claimed |
| US-8716303-B2 | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2014-05-06 | — | — | US | claimed |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2010-11-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000795-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | JAK2, JAK1, BTK | AXL 889/4885MERTK 452/4885TYRO3 280/4885 |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | AXL 449/4885MERTK 794/4885TYRO3 25/4885 |
| US-20190111058-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | JAK1, JAK2, JAK3 | AXL 1052/4885MERTK 447/4885TYRO3 284/4885 |
| US-20220378791-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | JAK1, JAK2, JAK3 | AXL 1052/4885MERTK 447/4885TYRO3 284/4885 |
| US-20150065447-A1 | SURVIVAL BENEFIT IN PATIENTS WITH SOLID TUMORS WITH ELEVATED C-REACTIVE PROTEIN LEVELS | JAK2, STAT3, IL6 | AXL 589/4885MERTK 172/4885TYRO3 326/4885 |
| US-20150246046-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | JAK1, JAK2, JAK3 | AXL 1052/4885MERTK 447/4885TYRO3 284/4885 |
| US-20150342952-A1 | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 | JAK1, JAK2, MCL1 | AXL 1833/4885MERTK 293/4885TYRO3 947/4885 |
| US-20240091234-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | JAK2, JAK1, BTK | AXL 889/4885MERTK 452/4885TYRO3 280/4885 |
| US-20220226327-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | JAK1, ROCK1, JAK3 | AXL 1369/4885MERTK 1237/4885TYRO3 574/4885 |
| US-11324749-B2 | Combination therapy for treatment of hematological diseases | JAK1, JAK3, JAK2 | AXL 1288/4885MERTK 738/4885TYRO3 999/4885 |
| US-20240058343-A1 | TREATMENT OF URTICARIA USING JAK INHIBITORS | JAK1, JAK3, JAK2 | AXL 559/4885MERTK 507/4885TYRO3 116/4885 |
| US-20140221379-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | AXL 449/4885MERTK 794/4885TYRO3 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.